Report 58999 for Endometrial Hyperplasia Treatment
Treatment of endometrial hyperplasia with the insertion of a hormone-containing intrauterine device (IUD) is an accepted method to manage endometrial hyperplasia for patients with abnormal uterine bleeding who are unable to tolerate, or at high risk for complications of, oral megestrol, states Palmetto GBA in its February 2012 Medicare Advisory.
The jurisdiction 1 Medicare administrative contractor (J1 MAC) says it will reimburse IUD insertion services for patients who meet these criteria effective for dates of service on or after Feb. 1, 2012.
For proper reimbursement, do not report CPT® code 58300 Insertion of intrauterine device (IUD) for endometrial hyperplasia treatment with an IUD for a Medicare patient. Medicare does not allow payment for contraceptive devices or medication, and the claim will be auto-denied.
Palmetto advises providers to, instead, bill the following information to avoid unnecessary claim denials:
- CPT® code 58999 Unlisted procedure, female genital system
- ICD-9 codes 621.30-621.34
- Enter “hormone IUD” in the comment/narrative field
Read the Medicare Advisory report for other important coding information pertaining to fee-for-service providers who submit Medicare Part B claims to Palmetto GBA.
JF MAC Noridian Administrative Services recently updated its IUD (Hormone-Eluting) for Endometrial Hyperplasia local coverage determination (LCD), as well, to include coverage for treatment of endometrial hyperplasia with the insertion of a hormone-containing IUD. Guidance is the same with one exception: In item 19 of the CMS-1500 form or the electronic equivalent, enter “hormone IUD for endometrial hyperplasia.”